×
  • My Account
  • About
  • Omnipresent
  • Events
  • Work for us
  • Contact
  • Team Members

Browse

  • Journals
  • Media
  • Careers
  • Gold
  • Education
  • Covid-19
  • Journals
  • Media
  • Careers
  • Gold
  • Education
  • Covid-19
  • More
  • Login / Register
  • Journals
  • Media
  • Careers
  • Gold
  • Education
  • Covid-19
  • Login / Register

Login to continue

Members

Forgotten your password?

Create Account

Create your own personal healthcare feed, full of the latest content from across our divisions.

Register

You must accept all conditions before being able to view the post
Continue
Logo
Personalise Content

Omnipresent - Video

Filter By Therapeutic Area

Cardiology
Reproductive Health
Oncology
Innovations
Respiratory
Allergy & Immunology
Gastroenterology
Urology
Neurology
Diabetes
Nephrology
Dermatology
Hematology
Hepatology
Interventional Cardiology
Rheumatology
Other
Pharma
Microbiology & Infectious Diseases
Radiology

Filter By Content Type

Webinars
Blog
Interviews
News
Press Release
Video

ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 2)

17 Feb 2015 Hematology

Prof John Gribben and Prof Marek Trněný at ASH 2014: Mantle cell lymphoma advances (Part 1)

17 Feb 2015 Hematology

ASH 2014: New therapies for mantle cell lymphoma

17 Feb 2015 Hematology

The role of nurses for supporting patients with myeloma

12 Feb 2015 Oncology

Adjuvant chemotherapy use in breast cancer after introducing the Oncotype DX® Breast Cancer Assay

09 Feb 2015 Oncology
  • ←
  • 1
  • 2
  • 3
  • …
  • 17
  • 18
  • 19
  • 20
  • About us
  • Work for us
  • Omnipresent
  • Register
  • My Account
  • Contact
Copyright © 2021 European Medical Group LTD. All rights reserved. European Medical Group is for informational purposes and should not be considered medical advice, diagnosis or treatment recommendation.

Ts & Cs | Privacy Policy

Website by vercossa

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.

Accept